Articles By Dan Schell, Editorial Director of Life Science Leader

Termeer_450x300
What’s It Like Being A Termeer Fellow?
We reached out to four previous Termeer Network Fellows to find out how the program helped them and what they learned. Participants included Sun Altbach, founder and former CEO and president of PIC Therapeutics; Ana Maiques, CEO, Neuroelectrics; Stan Wang, founder & CEO, Thymmune Therapeutuics; and Natalie Yivgi-Ohana, CEO, Minovia Therapeutics.  Continue Reading..
  • A Cover Feature Four Years In The Making
    3/1/2022

    I’m not sure what prompted the response from Rachel Haurwitz. It was, after all, a simple “thank you” that I had sent her via LinkedIn back in November 2017 for contributing some comments to our 2018 outlook issue.

  • Can Caribou Biosciences Top 2021?
    3/1/2022

    In 2021, much of Rachel Haurwitz’ hard-earned on-the-job training over the past decade culminated in a series of significant milestones that will undoubtably help position Caribou Biosciences for future growth and success.

  • Is Biopharma At An Inflection Point Regarding Digital Transformation?
    3/1/2022

    Released in late 2021, Deloitte’s, “Gain An Edge With Leapfrog Digital Innovation” report talks about how the biopharma industry is at an inflection point when it comes to digital transformation.

  • Thanks To COVID, Your Culture May Need An Overhaul
    1/4/2022

    This biotech fortified its culture during the pandemic by creating an employee support group, a new performance-management program, a woman-focused initiative, and programs that give days off for volunteering and provide $1200/year for personal and family development goals.

  • Becoming A Clinical-Stage Biotech
    9/1/2021

    A Q&A with Laura Indolfi, CEO and cofounder of PanTher Therapeutics, which recently closed its Series A funding round and is preparing for its first clinical trials.

  • A Q&A With A Biotech Founder/Entrepreneur
    8/2/2021

    Since cofounding Kymera Therapeutics, Nello Mainolfi, Ph.D., has served as CSO, CTO, and now is president and CEO. He helped Kymera bring the first ever targeted protein degrader to the clinic, go public in 2020, and land significant partnerships with the likes of GSK, Vertex, and Sanofi. 

  • Life Sciences CEOs Assess Upcoming Business Risk
    6/1/2021

    We take a closer look at the data related to organizational growth risks included in a recent KPMG  “Global CEO Outlook” survey.

  • A Q&A With A COVID-Era New CEO
    5/3/2021

    David Horn Solomon, Ph.D., took on the role of CEO of Pharnext in April 2020, at the beginning of the pandemic and just after the company had seen it’s Phase 3 trial data rejected by the FDA.

  • CEO Q&A: Dr. Aoife Brennan
    5/3/2021

    Dr. Aoife Brennan, president and CEO of Synlogic, discusses how the pandemic has affected her company’s operations and clinical trials.

  • A Q&A With Bernie Zeiher Of Astellas
    4/1/2021

    Bernie Zeiher Of Astellas took on the dual role of CMO & President of Development in April 2018. Here he discusses how he adjusted to that job and some of the best practices he’s learned along the way.

  • CEO Q&A: Mary Szela
    2/1/2021

    Mary Szela spent 25 years in Big Pharma and the last 7 at three small biotechs. The CEO Of TriSalus Life Sciences discusses how she adapted during these career changes and some of the difficulties she encountered along the way.

  • Program Strives For More Females On Pharma Boards
    11/1/2019

    In this first of a series of articles dedicated to the Women in Bio Boardroom Ready program, we discuss what the program entails and feedback from some previous participants.

  • How To Avoid Data-Integrity Woes In Pharma
    11/1/2019

    This article discusses what should be addressed to mitigate enterprise risks as they pertain to data integrity. It also lists what data-integrity compliance issues you should assess when choosing a CDMO.

  • Program Winners Look Back On Year Of Change
    10/1/2019

    Laura Indolfi and Elizabeth O’Day discuss how being chosen for the Massachusetts Next Generation Initiative (MassNextGen) changed their respective biopharma companies.

Dan Schell author page headshot

Dan Schell



Dan Schell is the Editorial Director of Life Science Leader magazine. In this role, he works with the publication’s internal and external writers and editors on choosing the best topics for articles as well as refining all content to meet Life Science Leader’s high editorial standards. He has been with the magazine since it was launched in 2009. Prior to focusing exclusively on Life Science Leader, he worked as an editor and copy editor for the publication’s parent company, VertMarkets. He joined the company in 2000 after 10 years of working for HealthSouth in marketing and business development and four years at an advertising agency.